BioWorld

July 30, 2008

View Archived Issues

Rebounding Amgen Trumps Q2 Estimates Despite Profit Decline

Amgen Inc.'s second-quarter earnings outstripped Wall Street expectations and sent shares rising for the second day in a row, signaling a much-needed upturn following a year and a half of negative ESA headlines. (BioWorld Today) Read More

FDA Panel Backs Approval of Roche IL-6 Arthritis Drug

Read More

Intercept Gets $25M for Bile Acid Trials

Read More

Celator Raises $22.5M for CombiPlex Products Pipeline

Read More

Other News To Note

Read More

Clinic Roundup

Read More